A New Risk Score Based on Lipid Indicators for Patients with Advanced Hepatocellular Carcinoma

被引:0
|
作者
Wei, Xing [1 ]
Guo, Ziwei [2 ]
Zhang, Tingting [3 ]
Liang, Jun [1 ]
机构
[1] Peking Univ Int Hosp, Dept Med Oncol, Beijing, Peoples R China
[2] Double Crane Runchuang Technol Beijing Co Ltd, Dept Med, Beijing, Peoples R China
[3] Capital Med Univ, Natl Clin Res Ctr Digest Dis, State Key Lab Digest Hlth, Dept Gen Surg,Beijing Friendship Hosp, Beijing, Peoples R China
关键词
hepatocellular carcinoma; survival; prognosis; clinical response; risk score; DENSITY-LIPOPROTEIN-CHOLESTEROL; EMERGING ROLE; BIOMARKER; INDEX; RATIO;
D O I
10.2147/JHC.S505028
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The prognosis is extremely troubling in advanced hepatocellular carcinoma (HCC). Prognostic scores have been developed. Yet, the positive predictive values might appear inadequate. This retrospective study aimed to develop a quick and efficient risk score to assess prognosis and clinical response. Methods: A total of 391 hCC patients were enrolled and were divided into training and validation groups between 2015 and 2024. Patients were separated into high-risk and low-risk groups using X-tile software. Using the COX proportional risk model analysis method, we then created a risk score and examined them using Kaplan-Meier, time-dependent receiver operating characteristics (ROC) curve, and nomogram analysis. Results: In predicting overall survival (OS), free fatty acid/high-density lipoprotein cholesterol (FFHL), tumor size, and BCLC stage were independent prognostic variables. A new risk score was developed just above and used as a prognostic factor (p < 0.001 in the training and validation groups) and had a high time-dependent ROC for progress-free survival (PFS) (area under the curve [AUC] 0.688-0.789 in the training group; AUC 0.592-0.741 in the validation group) and OS (AUC 0.812-0.918 in the training group; AUC 0.692-0.981 in the validation group). In comparison to the best overall response (BOR), the score offered a more accurate evaluation of durable clinical benefit (DCB) (p < 0.001 in the training and validation group; p = 0.061 vs 0.001 in the training and validation group). Conclusion: A new score based on lipid markers is a useful tool for evaluating prognosis and distinguishing patients with DCB.
引用
收藏
页码:107 / 121
页数:15
相关论文
共 50 条
  • [1] Development of a novel lipid metabolism-based risk score model in hepatocellular carcinoma patients
    Wang, Wenjie
    Zhang, Chen
    Yu, Qihong
    Zheng, Xichuan
    Yin, Chuanzheng
    Yan, Xueke
    Liu, Gang
    Song, Zifang
    BMC GASTROENTEROLOGY, 2021, 21 (01)
  • [2] Development of a novel lipid metabolism-based risk score model in hepatocellular carcinoma patients
    Wenjie Wang
    Chen Zhang
    Qihong Yu
    Xichuan Zheng
    Chuanzheng Yin
    Xueke Yan
    Gang Liu
    Zifang Song
    BMC Gastroenterology, 21
  • [3] New multi inflammation indicators in advanced hepatocellular carcinoma patients receiving sorafenib
    Gardini, Andrea Casadei
    Garuti, Francesca
    Neri, Andrea
    Trevisani, Franco
    Cascinu, Stefano
    JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E833 - E833
  • [4] Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma
    Masayoshi Yada
    Akihide Masumoto
    Kenta Motomura
    Hirotaka Tajiri
    Yusuke Morita
    Hideo Suzuki
    Takeshi Senju
    Toshimasa Koyanagi
    World Journal of Gastroenterology, 2014, (35) : 12581 - 12587
  • [5] Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma
    Yada, Masayoshi
    Masumoto, Akihide
    Motomura, Kenta
    Tajiri, Hirotaka
    Morita, Yusuke
    Suzuki, Hideo
    Senju, Takeshi
    Koyanagi, Toshimasa
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (35) : 12581 - 12587
  • [6] To Look or Not to Look: A New Score for Stratifying Patients at Risk of Developing Hepatocellular Carcinoma
    Foerster, Friedrich
    Galle, Peter r.
    GASTROENTEROLOGY, 2025, 168 (03) : 459 - 460
  • [7] An internally validated new clinical prognostic score for patients with advanced hepatocellular carcinoma treated with sorafenib
    Bruixola, G.
    Diaz Beveridge, R.
    Nino, O. M.
    Reche, E.
    Salvador, C.
    Escoin, C.
    Akhoundova, D.
    Segura, A.
    Gimenez, A.
    Aparicio, J.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S441 - S441
  • [8] An internally validated new clinical and inflammation-based prognostic score for patients with advanced hepatocellular carcinoma treated with sorafenib
    Diaz-Beveridge, R.
    Bruixola, G.
    Lorente, D.
    Caballero, J.
    Rodrigo, E.
    Segura, A.
    Akhoundova, D.
    Gimenez, A.
    Aparicio, J.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2018, 20 (03): : 322 - 329
  • [9] An internally validated new clinical and inflammation-based prognostic score for patients with advanced hepatocellular carcinoma treated with sorafenib
    R. Diaz-Beveridge
    G. Bruixola
    D. Lorente
    J. Caballero
    E. Rodrigo
    Á. Segura
    D. Akhoundova
    A. Giménez
    J. Aparicio
    Clinical and Translational Oncology, 2018, 20 : 322 - 329
  • [10] Conventional and machine-learning based risk score on survival for patients with hepatocellular carcinoma
    Ho, Chun-Ting
    Su, Chien-Wei
    Tan, Elise Chia-Hui
    Huang, Yi-Hsiang
    Hou, Ming-Chih
    Wu, Jaw-Ching
    JOURNAL OF HEPATOLOGY, 2024, 80 : S398 - S398